These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 19061580)
1. Doxycycline for the treatment of cutaneous leishmaniasis. Masmoudi A; Dammak A; Chaaben H; Maalej N; Akrout F; Turki H Dermatol Online J; 2008 Aug; 14(8):22. PubMed ID: 19061580 [TBL] [Abstract][Full Text] [Related]
2. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis. Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655 [TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Wortmann G; Miller RS; Oster C; Jackson J; Aronson N Clin Infect Dis; 2002 Aug; 35(3):261-7. PubMed ID: 12115091 [TBL] [Abstract][Full Text] [Related]
4. Cutaneous leishmaniasis: successful treatment with itraconazole. Consigli J; Danielo C; Gallerano V; Papa M; Guidi A Int J Dermatol; 2006 Jan; 45(1):46-9. PubMed ID: 16426375 [TBL] [Abstract][Full Text] [Related]
5. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Llanos-Cuentas A; Tulliano G; Araujo-Castillo R; Miranda-Verastegui C; Santamaria-Castrellon G; Ramirez L; Lazo M; De Doncker S; Boelaert M; Robays J; Dujardin JC; Arevalo J; Chappuis F Clin Infect Dis; 2008 Jan; 46(2):223-31. PubMed ID: 18171254 [TBL] [Abstract][Full Text] [Related]
6. Childhood and adult cutaneous leishmaniasis in Tunisia. Zaraa I; Ishak F; Kort R; El Euch D; Mokni M; Chaker E; Ben Osman A Int J Dermatol; 2010 Jul; 49(7):790-3. PubMed ID: 20618499 [No Abstract] [Full Text] [Related]
7. Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate. Solomon M; Baum S; Barzilai A; Pavlotsky F; Trau H; Schwartz E J Eur Acad Dermatol Venereol; 2009 Oct; 23(10):1189-92. PubMed ID: 19298486 [TBL] [Abstract][Full Text] [Related]
8. A Therapeutic update on Cutaneous leishmaniasis. Bari AU; Rahman SB J Coll Physicians Surg Pak; 2003 Aug; 13(8):471-6. PubMed ID: 12921689 [TBL] [Abstract][Full Text] [Related]
9. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. Solomon M; Baum S; Barzilai A; Scope A; Trau H; Schwartz E J Am Acad Dermatol; 2007 Apr; 56(4):612-6. PubMed ID: 17276541 [TBL] [Abstract][Full Text] [Related]
10. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Soto J; Toledo J; Gutierrez P; Nicholls RS; Padilla J; Engel J; Fischer C; Voss A; Berman J Clin Infect Dis; 2001 Oct; 33(7):E57-61. PubMed ID: 11528586 [TBL] [Abstract][Full Text] [Related]
11. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Sadeghian G; Nilforoushzadeh MA Int J Dermatol; 2006 Jul; 45(7):819-21. PubMed ID: 16863518 [TBL] [Abstract][Full Text] [Related]
12. Miltefosine in cutaneous leishmaniasis. Rahman SB; ul Bari A; Mumtaz N J Coll Physicians Surg Pak; 2007 Mar; 17(3):132-5. PubMed ID: 17374296 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Layegh P; Yazdanpanah MJ; Vosugh EM; Pezeshkpoor F; Shakeri MT; Moghiman T Am J Trop Med Hyg; 2007 Jul; 77(1):99-101. PubMed ID: 17620637 [TBL] [Abstract][Full Text] [Related]
14. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Soto J; Valda-Rodriquez L; Toledo J; Vera-Navarro L; Luz M; Monasterios-Torrico H; Vega J; Berman J Am J Trop Med Hyg; 2004 Nov; 71(5):577-81. PubMed ID: 15569787 [TBL] [Abstract][Full Text] [Related]
16. [Management of cutaneous leishmaniasis in adults and children]. Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM Med Trop (Mars); 2005 Nov; 65(5):487-95. PubMed ID: 16465821 [TBL] [Abstract][Full Text] [Related]
17. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study. Esfandiarpour I; Dabiri SH Int J Dermatol; 2007 Aug; 46(8):848-52. PubMed ID: 17651170 [TBL] [Abstract][Full Text] [Related]
18. Alterations in phenotypic profiles of peripheral blood cells from patients with human American cutaneous leishmaniasis following treatment with an antimonial drug and a vaccine. Botelho AC; Mayrink W; Oliveira RC Acta Trop; 2009 Nov; 112(2):143-8. PubMed ID: 19631187 [TBL] [Abstract][Full Text] [Related]
19. A comparative controlled trial of intralesionally-administered zinc sulphate, hypertonic sodium chloride and pentavalent antimony compound against acute cutaneous leishmaniasis. Sharquie KE; Najim RA; Farjou IB Clin Exp Dermatol; 1997 Jul; 22(4):169-73. PubMed ID: 9499605 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of short-course intramuscular pentamidine isethionate treatment on Old World localized cutaneous leishmaniasis in 2 patients. Jauréguiberry S; Graby G; Caumes E Clin Infect Dis; 2006 Jun; 42(12):1812-3. PubMed ID: 16705598 [No Abstract] [Full Text] [Related] [Next] [New Search]